With several vaccines approaching approval, we forecast monthly vaccinations for the large advanced economies combining estimates of supply (using data from five leading developers) and demand (using consumer surveys).

In the US, we expect the first available doses to go to high-risk groups from mid-December onwards, leading to significant public health benefits from Q1 onwards, followed by widespread vaccination commencing in April.

Looking more broadly, we expect large shares of the population to be vaccinated by late Q2 in all major DMs. The UK is expected to vaccinate 50% of its population in March with the US and Canada following in April, and the EU, Japan, and Australia in May. As production becomes abundant in Q2, demand drives vaccination and surpasses 70% across DMs in the fall.

We explore a downside scenario where the AstraZeneca and Johnson & Johnson vaccines do not succeed and demand weakens. This scenario shows slower vaccinations in Europe, which is more reliant on these developers, but also less medium-run vaccinations elsewhere owing to weaker demand, which appears most fragile in the US and Japan.

While the exact timeline remains quite uncertain, this analysis reinforces our baseline forecast that widespread immunization should drive a sharp pickup in global growth starting in Q2.
Vaccinating the Population: A Timeline (Struyven/Bhushan)

Following encouraging trial results from Pfizer-BioNTech, Moderna and AstraZeneca, the FDA is likely to approve the Pfizer-BioNTech and Moderna vaccines in coming weeks with FDA Advisory Committee meetings on December 10 and possibly December 17, respectively. Based on comments from European Commission President Ursula von der Leyen, the European Medicines Agency (EMA) is likely to authorize the three leading vaccines by year-end. With market focus shifting from approval to actual distribution, we forecast monthly vaccinations for six major advanced economies in five steps:

1. **Global vaccine production**: We use monthly global production projections from our health care equity analysts for Pfizer-BioNTech, Moderna, AstraZeneca, Novavax, and Johnson & Johnson. The projections assume that production gradually rises in early 2021 and achieves the announced targets.

2. **Country vaccine supply**: To allocate production across countries, we use data on agreements of purchases and purchase options, shown in the left panel of Exhibit 1, and data on initial deliveries. We assume the production share a country receives from a developer rises in the country’s initial deliveries, confirmed purchases, optional purchases, and population but falls to zero when contracted and optional purchases are delivered or when cumulative deliveries across the five developers exceed 90% of the population.

3. **Country vaccine demand**: We use responses to the global Ipsos survey question of “From when a vaccine is available, when would you become vaccinated?” (Exhibit 1, right). This survey suggests that most people expect to wait some time before taking it.

---

1 The authors thank Salveen Richter, Terence Flynn and Keyur Parekh for their input.

2 We assume the country shares of monthly Pfizer-BioNTech and Moderna deliveries are a weighted average of its shares in initial deliveries (30% weight), confirmed purchases (20%), optional purchases (15%), and its population (35%). While the exact allocation is unknown, these weights imply early US deliveries closely matching guidance from public health officials.
consistent with wanting to learn more about safety, side effects, and effectiveness. We also assume that demand will be more elevated and front-loaded than reported in the October Ipsos survey, which preceded recent trial results and upcoming public vaccination campaigns.\(^3\) Based on the expected timing of trials for children, we assume vaccinations for children under age 12 start globally in October 2021.

4. Vaccine distribution capacity: We assume a speed limit on distribution that rises from 10% of the population in December to 20% of the population from February 2021 onwards based on the peak speed of the flu vaccine US distribution this year, corresponding to 20% of the population per month.\(^4\)

5. Country vaccinations: We estimate monthly vaccination as the minimum of supply, demand, and distribution capacity.\(^5\)

Exhibit 2 illustrates the estimates of supply (light blue), demand (dark blue), and actual vaccinations (dotted green line) for the US and Canada. In both countries, vaccination is initially significantly limited by scarce supply, until additional capacity allows supply to exceed slowing demand in April. In Canada, the speed limit on distribution binds briefly in April. Demand drives vaccination from April in the US and May in Canada, rises gradually over the summer based on survey estimates, increases significantly with child vaccinations in the fall, and jumps past 70% in October in both countries.

---

3 To incorporate these expected increases in demand, we adjust the surveys following two approaches and then take a weighted average across approaches. First, we assume that 50% of those who said ‘not sure’ move to one of the categories with a timeframe of less than a year. Second, we assume that everyone moves forward two categories, with for instance ‘within 1 month’ and ‘within 3 months’ moving to ‘immediately’.

4 While more limited experience with Covid-19 vaccines, the double dose regimen, and cold storage requirements suggest a slower distribution relative to the flu vaccine, the large resources and public focus on distributing Covid vaccines suggest a faster distribution.

5 For simplicity, we count vaccination starting from the first dose onwards even though most leading vaccines will require a second shot delivered 3-4 weeks later.
Exhibit 3 shows our expected timeline for actual US vaccinations by tiering phase. High-risk groups, mostly health care workers and individuals with comorbid conditions, will likely receive the first available doses from mid-December, likely leading to significant public health benefits from Q1 onwards, followed by widespread vaccination from early April.

Exhibit 3: We Expect the First Available US Doses to Go to High-Risk Groups from December Onwards Followed by Widespread Vaccination Commencing in April

Looking more broadly, our baseline forecast is that large shares of the population are vaccinated by the end of Q2 in all major DMs (Exhibit 4). The UK is expected to vaccinate 50% of its population in March with the US and Canada following in April. We forecast that the EU, Japan, and Australia reach this 50% threshold in May. As production becomes abundant by mid-Q2, vaccination rises gradually with demand and surpasses 70% across all DMs in the fall when children become eligible.
We next explore a downside scenario. This scenario assumes that (1) the AstraZeneca and Johnson & Johnson vaccines, which are both viral vector vaccines, do not succeed (perhaps reflecting safety events), and (2) vaccine demand measures fall back to October 2020 Ipsos survey levels. In this scenario, supply rises much more slowly in the EU, reflecting a larger reliance on both developers. In the medium run, vaccination levels are the lowest in the EU (assuming no new contracts are signed) but also the US and Japan, where the decline in demand leaves vaccination at relatively low long-term levels. In contrast, Australia and Canada are more resilient, benefiting from diversified supply contracts and relatively strong vaccine demand measures.
The medium-run effects of the various vaccine candidates, their impact on transmission, vaccine supply, and especially vaccine demand remain quite uncertain and imply that risks are skewed to a later timeline. Moving in the other direction, the global vaccine pipeline is deeper than the top-5 Western candidates our simulations consider. Taken together, this analysis reinforces our baseline forecast that widespread immunization should drive a sharp pickup in global growth starting in Q2.

**Daan Struyven**

**Sid Bhushan**
Disclosure Appendix

Reg AC
We, Jan Hatzius, Daan Struyven, Sid Bhushan and Daniel Milo, hereby certify that all of the views expressed in this report accurately reflect our personal views, which have not been influenced by considerations of the firm’s business or client relationships. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs’ Global Investment Research division.

Disclosures

Regulatory disclosures

Disclosures required by United States laws and regulations
See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: Ownership and material conflicts of interest: Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. Analyst as owner: Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst’s area of coverage. Non-U.S. Analysts: Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States
The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. Australia: Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for “wholesale clients” within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of the Global Investment Research Division of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client’s objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriate advice having regard to the client’s own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs’ Australian Self-Regulatory Code of Conduct and Independence Policy Statement are available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. Brazil: Disclosure information in relation to CVM Instruction 598 is available at https://www.gs.com/worldwide/brazil/area/qi/index.html. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Instruction 598, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. Canada: Goldman Sachs Canada Inc. is an affiliate of The Goldman Sachs Group Inc. and therefore is included in the company specific disclosures relating to Goldman Sachs (as defined above). Goldman Sachs Canada Inc. has approved of, and agreed to take responsibility for, this research report in Canada if and to the extent that Goldman Sachs Canada Inc. disseminates this research report to its clients. Hong Kong: Further information on the securities of covered companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C. India: Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number IN000001493, 961-A, Rational House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Japan: See below. Korea: This research, and any access to it, is intended only for “professional investors” within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. New Zealand: Goldman Sachs New Zealand Limited and its affiliates are neither “registered banks” nor “deposit takers” (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for “wholesale clients” (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. Russia: Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. Singapore: Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. Taiwan: Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. United Kingdom: Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risk warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at https://www.gs.com/disclosures/europeanpolicy.html which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan and Type II Financial Instruments Firms Association. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to

26 November 2020 7
any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Global product; distributing entities

The Global Investment Research Division of Goldman Sachs produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Ombudsman Goldman Sachs Brazil; 0800 727 5784 and / or ouvidoriagoldmansachs@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by either Goldman Sachs Canada Inc. or Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom and European Union.

European Union: Goldman Sachs International authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, has approved this research in connection with its distribution in the European Union and United Kingdom.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but regulations may prevent us from doing so.荨We may disseminate, distribute, and present research content to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request access from doing so.荨Certain data underlying analysts’ fundamental analysis available on our internal client websites be delivered to them electronically through data services (that may be available to you, please contact your GS representative or go to research by third party aggregators). For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to https://www.sipc.org.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by our Global Investment Research Division. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (https://www.sipc.org).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

We and our affiliates, officers, directors, and employees, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is focused on investment themes across markets, industries and sectors. It does not attempt to distinguish between the prospects or performance of, or provide analysis of, individual companies within any industry or sector we describe.

Any trading recommendation in this research relating to an equity or credit security or securities within an industry or sector is reflective of the investment theme being discussed and is not a recommendation of any such security in isolation.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of your original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at https://www.thecoc.com/about/publications/character-risks.jsp and https://www.gdasc.com/publications/regulatory-disclosures/1/taa-regulatory-disclosures-booklet-pdf-version-2018.

Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by the Global Investment Research Division of GS may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts’ fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst’s fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to https://research.gs.com.

Disclosure information is also available at https://www.gs.com/research/hedge.html or from Research Compliance, 200 West Street, New York, NY 10282.

© 2020 Goldman Sachs.

No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written